Monteverde & Associates Investigates Quipt Home Medical Corp. Sale at $3.65 per Share

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Dec 15 2025

0mins

QIPT0%

Should l Buy QIPT?

Source: PRnewswire

Shareholder Rights Protection: Monteverde & Associates is investigating the sale of Quipt Home Medical Corp. to Kingswood Capital Management, where shareholders are expected to receive $3.65 per share in cash, raising questions about the fairness of the deal which could impact shareholder investment decisions.
Legal Firm Strength: Recognized as a Top 50 firm in the 2024 ISS Securities Class Action Services Report, Monteverde's strong track record in protecting shareholder rights enhances its reputation and credibility in the market.
Headquarters Advantage: Based in the Empire State Building, Monteverde & Associates leverages its national presence as a class action securities firm to effectively provide legal support to shareholders, improving accessibility to its services.
No-Risk Consultation: The firm offers free legal consultations, encouraging shareholders to obtain more information without cost or obligation, thereby increasing trust and reliance on its services among shareholders.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy QIPT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on QIPT

Wall Street analysts forecast QIPT stock price to rise

3 Analyst Rating

1 Buy

1 Hold

1 Sell

Hold

Current: 3.570

Low

3.65

Averages

3.77

High

4.00

Current: 3.570

Low

3.65

Averages

3.77

High

4.00

Canaccord

Richard Close

Hold

maintain

2025-12-17

Reason

Canaccord

Richard Close

Price Target

AI Analysis

2025-12-17

maintain

Hold

Reason

Canaccord analyst Richard Close raised the firm's price target on Quipt Home Medical to $3.65 from $2.30 and keeps a Hold rating on the shares. The firm updated its model after they reported 4QFY'25 results that beat expectations, in addition to a takeprivate transaction at $3.65 US per share with Kingswood Capital Management and Forager Capital Management.

Canaccord

Richard Close

Hold

maintain

2025-08-19

Reason

Canaccord

Richard Close

Price Target

2025-08-19

maintain

Hold

Reason

Canaccord analyst Richard Close raised the firm's price target on Quipt Home Medical (QIPT) to $2.30 from $1.70 and keeps a Hold rating on the shares. The firm said they demonstrated improvement in 3Q with a sequential uptick across metrics, though it remains down year over year as the company works through some headwinds such as its Humana MA (HUM) capitated contract and disposable supply contract non-renewal.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for QIPT

Unlock Now

About QIPT

Quipt Home Medical Corp. provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. The Company's expertise spans across a full spectrum of respiratory care, providing an end-to-end solution for medical providers and patients. This includes technology enabled equipment offerings and specialized care for patients with cardio and pulmonary diseases, sleep disorders, mobility challenges, and other chronic disease management. The Company's healthcare products and services include sleep apnea and pap treatment, home medical equipment, home ventilation and custom mobility solutions. It has a 60% ownership interest in Hart Medical Equipment, which maintains strategic relationships with integrated health systems and freestanding community-based hospitals, embedding the business into the hospital discharge processes of more than 19 hospitals and affiliated care facilities across its network.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Investor Rights Law Firm Investigates Multiple Companies

5 days agoPRnewswire

Shareholder Rights Investigation: Halper Sadeh LLC is investigating Quipt Home Medical Corp. (NASDAQ:QIPT) regarding its sale to Kingswood Capital Management and Forager Capital Management for $3.65 per share, which may infringe on shareholder rights.
Merger Impact Analysis: The merger of Sonida Senior Living, Inc. (NYSE:SNDA) with CNL Healthcare Properties will result in existing shareholders owning between 39.5% and 50.0% of the newly combined company's diluted common equity, potentially affecting shareholder control.
Shareholder Rights Protection: Following the merger of FirstSun Capital Bancorp (NASDAQ:FSUN) with First Foundation Inc., FirstSun shareholders will own 59.5% of the combined company, and Halper Sadeh LLC may seek increased compensation for shareholders.
Post-Merger Equity Distribution: The merger between Tamboran Resources Corporation (NYSE:TBN) and Falcon Oil & Gas Ltd. will allow Tamboran shareholders to retain 73.2% ownership in the combined entity, with Halper Sadeh LLC representing shareholders in seeking additional disclosures and rights protection.

Quipt Home Medical to Hold Special Shareholder Meeting

Feb 04 2026Newsfilter

Special Meeting Announcement: Quipt Home Medical will hold a special shareholder meeting on March 3, 2026, to vote on a proposal to acquire all outstanding shares at $3.65 each, representing a 54% premium over the 30-day VWAP as of December 12, 2025, which is expected to significantly enhance shareholder value.
Voting Support Agreements: The entire board and executive officers of Quipt, holding approximately 11.3% of the shares, have entered into voting support agreements with the acquirer, committing to vote in favor of the arrangement at the meeting, indicating strong management backing for the transaction.
Interim Court Order: The Supreme Court of British Columbia issued an interim order on January 23, 2026, authorizing the calling of the meeting and setting procedures for its conduct, providing legal assurance for the arrangement's implementation and ensuring compliance.
Encouragement for Shareholder Voting: Quipt encourages all shareholders to vote by proxy ahead of the February 27, 2026 deadline at 10:00 a.m. (Eastern Standard Time), ensuring that every shareholder's voice is heard and promoting transparency in decision-making.

Quipt Home Medical to Hold Special Shareholder Meeting

Feb 04 2026Yahoo Finance

Special Meeting Announcement: Quipt Home Medical will hold a special shareholder meeting on March 3, 2026, where shareholders will vote on a proposal to sell all outstanding shares for $3.65 each, representing a 54% premium over the 30-day VWAP as of December 12, 2025, which could significantly alter the company's shareholder structure and future direction.
Voting Support Agreements: The entire board and executive officers of Quipt, holding approximately 11.3% of shares, have entered into voting support agreements with the acquirer, committing to vote in favor of the arrangement resolution, which may bolster shareholder confidence in the transaction.
Interim Order Received: The Supreme Court of British Columbia issued an interim order on January 23, 2026, authorizing the calling of the meeting and establishing procedures for its conduct, providing legal backing for the arrangement's implementation and ensuring the transaction proceeds smoothly.
Encouragement for Shareholder Voting: The company urges all shareholders to vote in advance of the February 27, 2026, deadline at 10:00 a.m. (Eastern Standard Time), aiming to enhance shareholder engagement and secure the necessary approvals for the transaction to achieve its strategic objectives.

Ademi Firm Investigates Quipt's $260M Transaction with Kingswood for Fiduciary Breaches

Dec 16 2025PRnewswire

Investigation Launched: The Ademi Firm is investigating Quipt's transaction with Kingswood for potential breaches of fiduciary duty and legal violations, focusing on whether the Quipt board is fulfilling its responsibilities to all shareholders.
Transaction Valuation: In this deal, Quipt shareholders will receive $3.65 per share, valuing the company at approximately $260 million, including its existing outstanding debt, indicating a significant impact on the company's financial standing.
Competition Restrictions: The transaction agreement imposes significant penalties on Quipt for accepting competing bids, which could harm shareholder interests and lead to legal disputes regarding the board's conduct.
Insider Benefits: Quipt insiders will receive substantial benefits as part of the change of control arrangements, raising concerns about the board's actions and potentially affecting the transparency of corporate governance and shareholder trust.

Quipt Home Medical to Sell for $3.65 per Share to Kingswood and Forager

Dec 16 2025PRnewswire

Shareholder Rights Investigation: Halper Sadeh LLC is investigating Quipt Home Medical Corp.'s sale for $3.65 per share, which may violate federal securities laws and impact shareholder rights.
Merger Transaction Impact: The merger between Fifth Third Bancorp and Comerica Incorporated will result in Fifth Third shareholders owning approximately 73% of the combined entity, potentially altering shareholder control and corporate governance structures.
Potential Payment Rights: Generation Bio Co. is being sold for $4.2913 per share, along with a non-transferable contingent value right, which could provide shareholders with additional potential payments, enhancing investment appeal.
Legal Rights Protection: Halper Sadeh LLC offers free consultations to help shareholders understand their legal rights and options, aiming to secure increased consideration and additional disclosures for affected investors.